Small Pharma Analyst
Growth, long/short equity, biotech, healthcare

Antares: Uncertainty Creates An Exceptional Buying Opportunity

The focus of this article is to better understand the impact on Antares Pharma (NASDAQ:ATRS) of the dispute between Antares and privately-held Medac Pharma over patents regarding subcutaneous formulations of methotrexate and the impending PDUFA date for approval of Medac's competing product, Rasuvo.

As background, Antares Pharma focuses on developing and commercializing self-administered subcutaneous pharmaceutical products based on three principal technology platforms: (1) Vision reusable needle-free injectors; (2) Vibex disposable pressure-assisted auto-injectors; and (3) disposable multi-use pen injectors. ATRS has four approved products. TevTropin, Gelnique and Elestrin are products sold by partners with ATRS receiving royalty or licensing income. Otrexup, a subcutaneous formulation of methotrexate for the treatment of arthritis and psoriasis, is the first proprietary product that...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details